ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
ACC 2025: Oral Semaglutide Reduces Cardiovascular Events by 14% at 4 Years
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation
ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement